Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 9/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 10/20 | 0.40 |
| ▸ | CA2 | P00918 | 10/20 | 0.40 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | CA3 | P07451 | 7/20 | 0.40 |
| ▸ | CA4 | P22748 | 7/20 | 0.40 |
| ▸ | CA6 | P23280 | 7/20 | 0.40 |
| ▸ | CA5A | P35218 | 7/20 | 0.40 |
| ▸ | CA7 | P43166 | 7/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 7/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.37 |
| ▸ | CCKBR | P32239 | 2/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.36 |
| ▸ | CD47 | Q08722 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18476511 | 0.94 | CA9 (0.43) | CA9ALBCA1CA2CA12 | |
| SCHEMBL18475599 | 0.90 | FOLH1 (0.43) | MC4RCCKBRFOLH1CD47 | |
| SCHEMBL16983571 | 0.85 | CA9 (0.53) | CA9ALBCA1CA2CA12 | |
| SCHEMBL18475597 | 0.82 | FOLH1 (0.45) | MC4RCCKBRFOLH1CD47 | |
| SCHEMBL18475601 | 0.81 | CA9 (0.49) | CA9ALBCA1CA2CA12 | |
| SCHEMBL16983568 | 0.80 | CA2 (0.52) | CA9ALBCA1CA2CA12 | |
| SCHEMBL19153307 | 0.79 | CA9 (0.47) | CA9ALBCA1CA2CA12 | |
| SCHEMBL26258159 | 0.76 | CA9 (0.47) | CA9ALBCA1CA2CA12 | |
| SCHEMBL26258181 | 0.75 | CA9 (0.47) | CA9ALBCA1CA2CA12 | |
| SCHEMBL16983601 | 0.73 | FOLH1 (0.57) | CCKBRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381324-A1 | SMALL MOLECULE DRUG CONJUGATES | EIDGENOESSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2023-11-30 | — | — | US | disclosed |
| US-20210308269-A1 | Small Molecule Drug Conjugates | EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2021-10-07 | — | — | US | disclosed |
| US-10016511-B2 | Small molecule drug conjugates | ETH ZURICH (CH) | 2018-07-10 | — | — | US | disclosed |
| US-9884122-B2 | Small molecule drug conjugates | ETH ZURICH (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20170224831-A1 | Small Molecule Drug Conjugates | ETH ZURICH (CH) | 2017-08-10 | — | — | US | disclosed |
| US-20170035892-A1 | Small Molecule Drug Conjugates | ETH ZURICH (CH) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381324-A1 | SMALL MOLECULE DRUG CONJUGATES | CA9, CA12, CA2 | CA9 1/4885ALB 2274/4885CA1 10/4885 |
| US-20210308269-A1 | Small Molecule Drug Conjugates | CA9, CA12, CA2 | CA9 1/4885ALB 2274/4885CA1 10/4885 |
| US-20170035892-A1 | Small Molecule Drug Conjugates | CA9, CA11, CA4 | CA9 1/4885ALB 2848/4885CA1 6/4885 |
| US-10016511-B2 | Small molecule drug conjugates | CA9, CA12, CA2 | CA9 1/4885ALB 2274/4885CA1 10/4885 |
| US-20170224831-A1 | Small Molecule Drug Conjugates | CA9, CA12, CA2 | CA9 1/4885ALB 2274/4885CA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.